OSE Immunotherapeutics Announces Participation In Upcoming Investor Conferences
08 September 2022 - 06:00PM
Business Wire
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE) announced today that the leadership team will attend
several investor conferences in September and October 2022.
Conference details:
- H.C. Wainwright 24th Annual Global Investment
Conference Format: Fireside chat with H.C. Wainwright’s Equity
Research Associate, Sean Lee and Alexis Vandier, OSE
Immunotherapeutics’ Chief Executive Officer Date: September 12-14,
2022 Location: New York, USA and virtually
- Amsterdam Midcap Event Format: Investor meetings Date:
September 19, 2022 Location: Virtually
- Investor Access Event Format: Investor meetings Date:
October 6 & 7, 2022 Location: Paris, FR
- HealthTech Innovation Days Format: Investor meetings
Date: October 13 & 14, 2022 Location: Paris, FR
- European Midcap Event Format: Investor meetings Date:
October 17 & 18, 2022 Location: Paris, FR
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is an
integrated biotechnology company focused on developing and
partnering therapies to control the immune system for
Immuno-Oncology and Immuno-Inflammation. Its balanced
first-in-class clinical and preclinical portfolio has a diversified
risk profile:
Immuno-Oncology first-in-class products - Tedopi®
(innovative neoepitope combination): the Company’s most advanced
product; positive results for Phase 3 trial (Atalante 1) in
Non-Small Cell Lung Cancer patients in secondary resistance after
checkpoint inhibitor failure. Other ongoing combination trials
sponsored by cooperative clinical research groups in oncology:
Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR. Phase 2 in
ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor
ARCAGY-GINECO. Phase 2 in non-small cell lung cancer in combination
with nivolumab, sponsor Italian foundation FoRT. - BI 765063
(OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in
partnership with Boehringer Ingelheim in advanced solid tumors;
positive Phase 1 dose escalation results of BI 765063 in
monotherapy and in combination with ezabenlimab (PD-1 antagonist);
ongoing expansion Phase 1; BI sponsored international phase 1b
clinical trial ongoing in combination with ezabenlimab alone or
with other drugs in patients with recurrent/metastatic head and
neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma
(HCC). - OSE-279, anti-PD1 – advanced preclinical stage. -
BiCKI®: bispecific fusion protein platform built on the key
backbone component of anti-PD1 combined with a new immunotherapy
target (for example: BiCKI®-IL7, preclinical stage) to increase
anti-tumor efficacy. Immuno-Inflammation first-in-class
products - OSE-127/S95011 (humanized monoclonal antibody
antagonist of IL-7 receptor): developed in partnership with
Servier; positive Phase 1 results; ongoing Phase 2 in ulcerative
colitis (sponsor OSE) and ongoing Phase 2a in Sj�gren’s syndrome
(sponsor Servier). - FR104 (anti-CD28 monoclonal antibody):
licensing partnership agreement with Veloxis Pharmaceuticals, Inc.
in transplantation; ongoing Phase 1/2 in renal transplant
(sponsored by the Nantes University Hospital); Phase 1 ongoing in
the US (VEL-101, sponsor Veloxis Pharmaceuticals, Inc.); Phase 2
planned in an autoimmune disease indication. - OSE-230
(ChemR23 agonist mAb): preclinical stage therapeutic agent with the
potential to resolve chronic inflammation by driving affected
tissues to tissue integrity. CoVepiT: a prophylactic
second-generation vaccine activating cytotoxic T lymphocytes
against COVID-19, developed using optimized epitopes from SARS-CoV2
viral proteins, epitopes non impacted by multi-variants. Shows good
tolerance and very good level of T cell immune response. In
clinical testing, a long-term memory response was confirmed at 6
months. Click and follow us on Twitter and LinkedIn
Forward-looking statements This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are
based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate. These forward-looking statements include
statements typically using conditional and containing verbs such as
“expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”,
their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on 15 April 2022, including the annual financial
report for the fiscal year 2021, available on the OSE
Immunotherapeutics’ website. Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date
hereof and does not undertake any obligation to update or revise
the forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220908005687/en/
OSE Immunotherapeutics Sylvie Détry
sylvie.detry@ose-immuno.com +33 153 198 757
Investor Relations Thomas Guillot
thomas.guillot@ose-immuno.com +33 607 380 431
French Media: FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 607 768 283
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Mär 2023 bis Mär 2024